File(s) under permanent embargo
Antithrombotic Therapy Duration after Patent Foramen Ovale Closure for Stroke Prevention: Impact on Long-Term Outcome
journal contribution
posted on 2023-05-19, 04:50 authored by Joelle Kefer, Karlien Carbonez, Sophie Pierard, Francois-Pierre Mouthuy, Anna PeetersAnna Peeters, Cedric Hermans, Catherine Lambert, Christophe DeMeester, Thierry Sluysmans, Agnes PasquetBackground. The optimal duration of antithrombotic therapy (ATT) after patent foramen ovale (PFO) closure remains under debate. This study sought to compare the clinical outcome of patients receiving antithrombotic agents for a short (6 months) versus extended (>6 months) period after the procedure. Methods. This was a retrospective cohort study using a propensity score matching analysis on 259 consecutive patients (131 males, 43 ± 10 years) undergoing PFO closure due to cryptogenic stroke, with complete follow-up (median duration of 10 [4–13] years). The outcome was compared between patients receiving short-term (Group short, N = 88) versus extended ATT (Group long, N = 171). Results. The PFO closure device was successfully implanted in all cases, with 3% of minor complications. After propensity score matching, there were no differences between Groups short and long in the rate of stroke (0.3 vs. 0.4% patient-year,
), bleeding (2 vs. 2% patient-year,
), and device thrombosis (0.3 vs. 0.1% patient-year;
). Univariate analysis showed that short-term ATT was not associated with an increased risk of recurrent stroke (HR: 1.271 [95% CI: 0.247–6.551],
) or prosthesis thrombus (HR: 0.50 [95% CI: 0.070–3.548],
). Kaplan–Meier analysis revealed similar overall survival in Group short and long (100 vs. 99 ± 1%, respectively;
). Conclusions. Short-term (6 months) ATT after PFO closure did not impair the clinical outcome, with a preserved low rate of recurrent stroke (0.3% patient-year) and device thrombosis (0.2% patient-year) at 10-year follow-up.
History
Journal
JOURNAL OF INTERVENTIONAL CARDIOLOGYVolume
2022Article number
ARTN 6559447Location
United StatesPublisher DOI
ISSN
0896-4327eISSN
1540-8183Language
EnglishPublication classification
C1.1 Refereed article in a scholarly journalEditor/Contributor(s)
Dens JPublisher
WILEY-HINDAWIUsage metrics
Keywords
Science & TechnologyLife Sciences & BiomedicineCardiac & Cardiovascular SystemsCardiovascular System & CardiologyMEDICAL THERAPYANTIPLATELET THERAPYSEPTAL-DEFECTFOLLOW-UPDEFINITIONSMaleHumansForamen Ovale, PatentFibrinolytic AgentsSecondary PreventionRetrospective StudiesStrokeTreatment OutcomeSeptal Occluder DeviceRecurrenceCardiac CatheterizationClinical ResearchBrain DisordersHematologyCardiovascular6.4 Surgery6 Evaluation of treatments and therapeutic interventionsCardiorespiratory Medicine and Haematology not elsewhere classified
Licence
Exports
RefWorks
BibTeX
Ref. manager
Endnote
DataCite
NLM
DC